(Q38339098)

2 September 2017

1 reference

title

Familial gastric cancer: genetic susceptibility, pathology, and implications for management (English)

1 reference

2 September 2017

1

1 reference

2 September 2017

2

1 reference

2 September 2017

Joana Figueiredo

3

0 references

Raquel Seruca

object named as

Raquel Seruca

series ordinal

4

0 references

Fatima Carneiro

object named as

Fátima Carneiro

series ordinal

5

0 references

publication date

1 February 2015

1 reference

Lancet Oncology Commission

2 September 2017

published in

1 reference

2 September 2017

volume

16

1 reference

2 September 2017

issue

2

1 reference

2 September 2017

page(s)

e60-70

1 reference

The two histological main types of gastric carcinoma: diffuse and so called intestinal-type carcinoma: an attempt at a histo-clinical classification

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

The epidemiology of gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Family history and the risk of stomach and colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

E-cadherin germline mutations in familial gastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

An α-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

E-cadherin alterations in hereditary disorders with emphasis on hereditary diffuse gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

De novo CDH1 mutation in a family presenting with early-onset diffuse gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Cleft lip/palate and CDH1/E-cadherin mutations in families with hereditary diffuse gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Familial fundic gland polyposis with gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

History, pathogenesis, and management of familial gastric cancer: original study of John XXIII's family

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Clinical utility gene card for: Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) - update 2012.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

The IARC TP53 database: new online mutation analysis and recommendations to users

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Gastric cancer in individuals with Li-Fraumeni syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

The genetics of FAP and FAP-like syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Guidelines for the clinical management of familial adenomatous polyposis (FAP).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Upper gastrointestinal cancer in patients with familial adenomatous polyposis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Gastric cancer: new genetic developments

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Morphology and natural history of familial adenomatous polyposis-associated dysplastic fundic gland polyps.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Attenuated familial adenomatous polyposis (AFAP). A phenotypically and genotypically distinctive variant of FAP.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Total gastrectomy for gastric dysplasia in a patient with attenuated familial adenomatous polyposis syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

High cancer risk and increased mortality in patients with Peutz-Jeghers syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Hereditary polyposis syndromes and hereditary non-polyposis colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Cancer risks in BRCA2 mutation carriers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

A high frequency of BRCA2 gene mutations in Polish families with ovarian and stomach cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Germline E-cadherin Gene (CDH1) Mutations Predispose to Familial Gastric Cancer and Colorectal Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Germline CDH1 deletions in hereditary diffuse gastric cancer families

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Clinical implications of E-cadherin associated hereditary diffuse gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

A model to infer the pathogenic significance of CDH1 germline missense variants

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

E-cadherin destabilization accounts for the pathogenicity of missense mutations in hereditary diffuse gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

The importance of E-cadherin binding partners to evaluate the pathogenicity of E-cadherin missense mutations associated to HDGC.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Convex total variation denoising of Poisson fluorescence confocal images with anisotropic filtering.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Quantification of mutant E-cadherin using bioimaging analysis of in situ fluorescence microscopy. A new approach to CDH1 missense variants.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Histopathological and molecular analysis of gastrectomy specimens from hereditary diffuse gastric cancer patients has implications for endoscopic surveillance of individuals at risk

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Complementary molecular approaches reveal heterogeneous CDH1 germline defects in Italian patients with hereditary diffuse gastric cancer (HDGC) syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Quantification of epigenetic and genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Somatic Mutations and Deletions of the E-Cadherin Gene Predict Poor Survival of Patients With Gastric Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Germline mutations in MAP3K6 are associated with familial gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Intragenic deletion of CDH1 as the inactivating mechanism of the wild-type allele in an HDGC tumour

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Destabilized adhesion in the gastric proliferative zone and c-Src kinase activation mark the development of early diffuse gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Chromoendoscopic surveillance in hereditary diffuse gastric cancer: an alternative to prophylactic gastrectomy?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Early Gastric Cancer in Young, Asymptomatic Carriers of Germ-Line E-Cadherin Mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Prospective cohort study assessing outcomes of patients from families fulfilling criteria for hereditary diffuse gastric cancer undergoing endoscopic surveillance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Clinical utility gene card for: Hereditary diffuse gastric cancer (HDGC)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Pregnancy after prophylactic total gastrectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Cancer syndromes and therapy by stop-codon readthrough

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Rescue of wild-type E-cadherin expression from nonsense-mutated cancer cells by a suppressor-tRNA

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

ADP-ribosylation factor 6 mediates E-cadherin recovery by chemical chaperones

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Induced DNA demethylation by targeting Ten-Eleven Translocation 2 to the human ICAM-1 promoter

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Direct cadherin-activated cell signaling: a view from the plasma membrane

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

New signals from the invasive front

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

EGFR regulates RhoA-GTP dependent cell motility in E-cadherin mutant cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Molecular targeted therapy for advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Therapeutic targets associated to E-cadherin dysfunction in gastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

E-cadherin dysfunction in gastric cancer--cellular consequences, clinical applications and open questions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

E-cadherin deficiency initiates gastric signet-ring cell carcinoma in mice and man.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Loss of E-cadherin in mouse gastric epithelial cells induces signet ring-like cells, a possible precursor lesion of diffuse gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

A targeted mutation in the mouse E-cadherin gene results in defective preimplantation development

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971016-2

7 January 2021

10.1016/S1470-2045(14)71016-2

Identifiers

DOI

1 reference

2 September 2017

1 reference